Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Leerink Partners Remains Bullish as Fate Therapeutics (FATE) Plans to Initiate ProTmune Study
March 4, 2016 9:49 AM ESTLeerink Partners maintained an Outperform rating on Fate Therapeutics (NASDAQ: FATE), and cut the price target to $4.00 (from $8.00), following the company's 4Q earnings report. FATE's reported EPS of ($0.26) was slightly better than estimate' of ($0.28). The company also announced that it anticipates initiating the Phase I/II study of ProTmune in... More
